TY - JOUR AU - Kovac, Mirjana AU - Ignjatovic, Vera AU - Orlando, Christelle AU - Bereczky, Zsuzsanna AU - Hunt, Beverley J TI - The use of DOACs in the secondary prevention of venous thromboembolism in patients with severe thrombophilia. communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. TS - communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. JF - JOURNAL OF THROMBOSIS AND HAEMOSTASIS J2 - J THROMB HAEMOST PY - 2024 SN - 1538-7933 DO - 10.1016/j.jtha.2024.08.006 UR - https://m2.mtmt.hu/api/publication/35306393 ID - 35306393 N1 - Journal Article; Practice Guideline AB - Direct Oral Anticoagulants (DOACs) are the first line anticoagulants for the secondary prevention of venous thromboembolism (VTE). However, patients with severe inherited thrombophilias represent a group where the efficiency and safety of DOACs is poorly studied. In this communication, we focus on the utility of DOACs in the secondary prevention of VTE in patients with severe thrombophilia. Current evidence is based only on cohort or single center studies, and poor data is available on compliance of the patients in the studies. Analysis of the studies suggested that full-dose DOACs and vitamin K antagonists (VKAs) have a similar efficacy and bleeding risk in the secondary prevention of VTE in patients with thrombophilia; with a low hazard ratio for recurrent VTE calculated from cohort studies for DOAC vs warfarin, ranging from 0.3 to 0.75. We wish to highlight that treatment failure is greater in those with severe forms of Protein S deficiency (below 20%), and possibly in AT deficiency Type II HBS homozygous Budapest 3. In summary, the current approach to using DOACs in patients with severe thrombophilia is dependent on clinical judgment and experience. Limited evidence suggests that for those with severe thrombophilias, full dose DOACs have similar utility as VKAs. We recommend caution in using low - dose DOACs due to lack of evidence. Ideally large randomized multicenter studies are required to develop a reliable treatment algorithm. LA - English DB - MTMT ER - TY - JOUR AU - Mátrai, Ádám Attila AU - Varga , Ádám AU - Baráth, Barbara AU - Ványolos, Erzsébet AU - Orbán-Kálmándi, Rita Angéla AU - Lóczi, Linda AU - Bagoly, Zsuzsa AU - Jouppila, Annukka AU - Lassila, Riitta AU - Németh, Norbert AU - Deák, Ádám TI - Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model JF - JOURNAL OF THROMBOSIS AND THROMBOLYSIS J2 - J THROMB THROMBOLYS PY - 2024 PG - 10 SN - 0929-5305 DO - 10.1007/s11239-024-03040-8 UR - https://m2.mtmt.hu/api/publication/35278395 ID - 35278395 LA - English DB - MTMT ER - TY - JOUR AU - Lóczi, Linda AU - P. Szabó, Réka AU - Orbán-Kálmándi, Rita Angéla AU - Rebeka, Hodossy-Takács AU - Anikó, Szilvási AU - Zoltán, Szalai AU - Szemán-Nagy, Gábor AU - Antal-Szalmás, Péter AU - Nemes, Balázs AU - Bagoly, Zsuzsa TI - Increased thrombin generation in kidney transplant recipients with donor-specific antibodies directed against human leukocyte antigens JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL PY - 2024 SN - 1664-3224 UR - https://m2.mtmt.hu/api/publication/35211816 ID - 35211816 LA - English DB - MTMT ER - TY - JOUR AU - Balogh, Gábor AU - Bereczky, Zsuzsanna TI - Molecular Mechanisms of the Impaired Heparin Pentasaccharide Interactions in 10 Antithrombin Heparin Binding Site Mutants Revealed by Enhanced Sampling Molecular Dynamics JF - BIOMOLECULES J2 - BIOMOLECULES VL - 14 PY - 2024 IS - 6 SP - 657 SN - 2218-273X DO - 10.3390/biom14060657 UR - https://m2.mtmt.hu/api/publication/34903749 ID - 34903749 AB - Antithrombin (AT) is a critical regulator of the coagulation cascade by inhibiting multiple coagulation factors including thrombin and FXa. Binding of heparinoids to this serpin enhances the inhibition considerably. Mutations located in the heparin binding site of AT result in thrombophilia in affected individuals. Our aim was to study 10 antithrombin mutations known to affect their heparin binding in a heparin pentasaccharide bound state using two molecular dynamics (MD) based methods providing enhanced sampling, GaMD and LiGaMD2. The latter provides an additional boost to the ligand and the most important binding site residues. From our GaMD simulations we were able to identify four variants (three affecting amino acid Arg47 and one affecting Lys114) that have a particularly large effect on binding. The additional acceleration provided by LiGaMD2 allowed us to study the consequences of several other mutants including those affecting Arg13 and Arg129. We were able to identify several conformational types by cluster analysis. Analysis of the simulation trajectories revealed the causes of the impaired pentasaccharide binding including pentasaccharide subunit conformational changes and altered allosteric pathways in the AT protein. Our results provide insights into the effects of AT mutations interfering with heparin binding at an atomic level and can facilitate the design or interpretation of in vitro experiments. LA - English DB - MTMT ER - TY - JOUR AU - Bagoly, Zsuzsa TI - Hemorrhagic transformation after acute ischemic stroke thrombolysis treatment: navigating the landscape of hemostasis genetic risk factors JF - JOURNAL OF THROMBOSIS AND HAEMOSTASIS J2 - J THROMB HAEMOST VL - 22 PY - 2024 IS - 4 SP - 919 EP - 921 PG - 3 SN - 1538-7933 DO - 10.1016/j.jtha.2024.01.002 UR - https://m2.mtmt.hu/api/publication/34898159 ID - 34898159 LA - English DB - MTMT ER - TY - JOUR AU - Kállai, Judit AU - Gindele, Réka AU - Pénzes-Daku, Krisztina AU - Balogh, Gábor AU - Kissné Bogáti, Réka AU - Bécsi, Bálint AU - Katona, Éva AU - Oláh, Zsolt AU - Ilonczai, Péter AU - Boda, Zoltán AU - Róna-Tas, Ágnes AU - Nemes, László AU - Marton, Imelda AU - Bereczky, Zsuzsanna TI - Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 5 PG - 19 SN - 1661-6596 DO - 10.3390/ijms25052893 UR - https://m2.mtmt.hu/api/publication/34742646 ID - 34742646 AB - Antithrombin (AT) is the major plasma inhibitor of thrombin (FIIa) and activated factor X (FXa), and antithrombin deficiency (ATD) is one of the most severe thrombophilic disorders. In this study, we identified nine novel AT mutations and investigated their genotype-phenotype correlations. Clinical and laboratory data from patients were collected, and the nine mutant AT proteins (p.Arg14Lys, p.Cys32Tyr, p.Arg78Gly, p.Met121Arg, p.Leu245Pro, p.Leu270Argfs*14, p.Asn450Ile, p.Gly456delins_Ala_Thr and p.Pro461Thr) were expressed in HEK293 cells; then, Western blotting, N-Glycosidase F digestion, and ELISA were used to detect wild-type and mutant AT. RT-qPCR was performed to determine the expression of AT mRNA from the transfected cells. Functional studies (AT activity in the presence and in the absence of heparin and heparin-binding studies with the surface plasmon resonance method) were carried out. Mutations were also investigated by in silico methods. Type I ATD caused by altered protein synthesis (p.Cys32Tyr, p.Leu270Argfs*14, p.Asn450Ile) or secretion disorder (p.Met121Arg, p.Leu245Pro, p.Gly456delins_Ala_Thr) was proved in six mutants, while type II heparin-binding-site ATD (p.Arg78Gly) and pleiotropic-effect ATD (p.Pro461Thr) were suggested in two mutants. Finally, the pathogenic role of p.Arg14Lys was equivocal. We provided evidence to understand the pathogenic nature of novel SERPINC1 mutations through in vitro expression studies. LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Eszter Lilla AU - Orbán-Kálmándi, Rita Angéla AU - Bagoly, Zsuzsa AU - Lóczi, Linda AU - Deli, Tamás AU - Török, Olga AU - Molnár, Sarolta AU - Baráth, Sándor AU - Singh, Parvind AU - Hevessy Zsuzsanna, Dóra AU - Katona, Éva AU - Fagyas, Miklós AU - Szabó, Attila Ádám AU - Molnár, Szabolcs AU - Krasznai, Zoárd Tibor TI - Case report: Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 15 PY - 2024 SP - 1 SN - 1664-3224 DO - 10.3389/fimmu.2024.1329236 UR - https://m2.mtmt.hu/api/publication/34719971 ID - 34719971 LA - English DB - MTMT ER - TY - CHAP AU - Bagoly, Zsuzsa ED - Bereczky, Zsuzsanna ED - Bagoly, Zsuzsa ED - Katona, Éva TI - Pályázatok írása, költségtervezés T2 - Klinikai kutatások - átfogó ismeretek a tervezéstől a közlésig PB - Medicina Könyvkiadó CY - Budapest SN - 9789632269115 PY - 2024 SP - 275 EP - 283 PG - 9 UR - https://m2.mtmt.hu/api/publication/34560620 ID - 34560620 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Bagoly, Zsuzsa ED - Bereczky, Zsuzsanna ED - Bagoly, Zsuzsa ED - Katona, Éva TI - Intézményen kívüli, multicentrikus és nemzetközi klinikai tanulmányok T2 - Klinikai kutatások - átfogó ismeretek a tervezéstől a közlésig PB - Medicina Könyvkiadó CY - Budapest SN - 9789632269115 PY - 2024 SP - 189 EP - 198 PG - 10 UR - https://m2.mtmt.hu/api/publication/34560606 ID - 34560606 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Katona, Éva ED - Bereczky, Zsuzsanna ED - Bagoly, Zsuzsa ED - Katona, Éva TI - A diagnosztikus tesztek fejlesztésének és validálásának szempontjai T2 - Klinikai kutatások - átfogó ismeretek a tervezéstől a közlésig PB - Medicina Könyvkiadó CY - Budapest SN - 9789632269115 PY - 2024 SP - 153 EP - 171 PG - 19 UR - https://m2.mtmt.hu/api/publication/34560595 ID - 34560595 LA - Hungarian DB - MTMT ER -